CHICAGO, April 08, 2020 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced today that it has signed a definitive agreement with SunMed Biosciences Limited to be the exclusive representative and distribution agent of a rapid Diagnostic Detection Kit (DDK) into four EU countries: Germany, England, Greece and Cyprus. Specifically, this product is used for qualitative detection of the presence of IgM and/or IgG antibody to SARS-CoV-2, virus that causes COVID-19, in human serum, plasma and whole blood. The Company looks forward to contributing in the fight against coronavirus utilizing its channels of distribution in the aforementioned geographic territories adding the DDK device to its portfolio of medical products for the protection and betterment of public health. Cosmos Holdings CEO Gregory Siokas commented, “We are glad to announce the exclusivity agreement with SunMed Biosciences which will enable us to significantly contribute to the fight against this pandemic by supplying this DDK device via our organization’s channels of distribution. Being on the frontline of this unprecedented situation, we will focus our efforts to assist in finding a resolution of the coronavirus situation using all means available from COSMOS HOLDINGS.”
Photo
David E. Gutierrez
Head of PR, IR
and Corporate Development

Join our mailing list to stay up to date.

Cosmos-logo